To determine selectivity, we divided the tumor-infiltrating CD4 and CD8 T cells into four subsets: CD4+CTLA4+Foxp3+, CD4+CTLA4−Foxp3+, CD4+CTLA4+Foxp3−, and CD8+CTLA4+Foxp3− based on profiles in Figure 1b and compared their response to HL-32 and Ipilimumab. The gene discussed is FOXP3; the disease is neoplasm.